Bexacat™ (bexagliflozin tablets) is indicated to improve glycemic
control in otherwise healthy cats with diabetes mellitus not previously
treated with insulin. Download the Patient Selection and Monitoring
sheet to help you choose the right patients to prescribe Bexacat and
understand the treatment monitoring guidelines:
https://assets.elanco.com/0cec44ed-3eaa-0009-2029-666567e7e4de/1b0d2a58-
023b-4ce1-948e-4f0f011c0eed/Bexacat%20Vet%20Patient%20Selection-Monitoring%20Sheet%20-%202nd%20update%20-%20Jan%202023.pdf

▪Sodium-glucose cotransporter 2 (SGLT2) inhibitor, this first-in-class
therapeutic is indicated to improve glycemic control in otherwise
healthy cats with diabetes mellitus not previously treated with insulin
▪For oral use in cats only
▪Minimal risk of hypoglycemia and no dosage changes during treatment
▪Convenient, needle-free, once-daily flavored tablet ensures dosing
certainty
▪No dose titration needed
▪No refrigeration required
▪Can be given with or without food